

18th March 2021

(1) BSE Limited
Listing Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: 500087

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Sub: Press Release - Cipla pledges support to 'Terra Carta', for a sustainable future

Dear Sir / Madam,

Please find enclosed press release dated 18th March 2021 for the captioned subject.

This is for your information and records.

Kindly acknowledge the receipt.

Thanking you,

**Yours faithfully,
For Cipla Limited**

**Rajendra Chopra
Company Secretary**

Encl.as above

Prepared by: Mandar Kurghode

Press Release

Cipla pledges support to 'Terra Carta', for a sustainable future

Cipla is the only Indian pharmaceutical company to join this global sustainability initiative

Mumbai; March 18, 2021: Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referred to as "Cipla" today announced that it has pledged support to 'Terra Carta', a landmark charter that has been drawn up to put sustainability at the heart of the private sector. The charter is part of HRH The Prince of Wales' Sustainable Markets Initiative that was launched in Davos in 2020, with founding partners such as Bank of America, HSBC, BP and NatWest among others.

Since its launch in January 2021, the initiative has received support from 223 private sector organisations and 21 professional associations. Cipla is one of the five Indian companies and the only Indian pharmaceutical company to participate.

While continuing to achieve its own environmental, social and governance (ESG) goals, Cipla would also have the opportunity to drive ESG discourse within the sector and at a regional level. At the same time, the initiative would allow participating organizations to cross-learn from one another.

Mr Umang Vohra, MD & Global CEO, Cipla said *"Achieving sustainable and equitable growth is one of the greatest challenges and the need of this century. The pandemic has shown what can be achieved with the power of the collective, and the healthcare and the pharma sector has been at the forefront of it. I commend HRH Prince of Wales for leading Terra Carta and bringing together business leaders on Agenda 2030. We are committed to contributing to these goals and look forward to working alongside other sectors and business leaders"*.

Cipla has been championing its ESG agenda towards developing a holistic sustainability road map for the future. Since FY19, Cipla has added 48 MW of solar energy portfolio through various initiatives such as an on-site roof top or ground mounted solar under RESCO model, third party solar open access power purchase agreement, and group captive solar open access project. The Company recently set up a 30 MW solar group captive project spread across 11 acres in Tuljapur, Maharashtra, making it one of the largest solar open access projects in the state set up by a corporate. By 2025, Cipla plans to achieve carbon and water neutrality, zero-waste to landfill, anti-microbial resistance stewardship and green chemistry.

For more information on Terra Carta and Sustainable Markets Initiative, please visit: <https://www.sustainable-markets.org/terra-carta/>

About Cipla:

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA December'20), 3rd largest in the pharma private market in South Africa (IQVIA MAT December'20), and is among the most dispensed generic

Cipla Ltd.

Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400013, India.

P +91 22 24826000 **F** +91 22 24826120 **W** www.cipla.com **E-Mail** contactus@cipla.com **Corporate Identity Number** L24239MH1935PLC002380

players in the U.S. For over eight decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit www.cipla.com, or click on Twitter, Facebook, LinkedIn.

For queries, please contact:

Corporate Communications

Heena Kanal

E-Mail: CorpComm@cipla.com

Investor Relations

Naveen Bansal

E-Mail: Investor.Relations@cipla.com